ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "osteoporosis"

  • Abstract Number: 1973 • ACR Convergence 2020

    Treatment Sequences with Romosozumab Before or After Antiresorptive Medication

    Felicia Cosman1, David Kendler2, Bente Langdahl3, Benjamin Z Leder4, E Michael Lewiecki5, Akimitsu Miyauchi6, Maria Rojeski7, Michele McDermott7, Mary Oates7, Cassandra E Milmont8, Cesar Libanati9 and Serge Ferrari10, 1Columbia University, New York, NY, 2University of British Columbia, Vancouver, BC, Canada, 3Aarhus University Hospital, Aarhus, Denmark, 4Mass General Hospital, Harvard Medical School, Boston, MA, Boston, MA, 5New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 6Miyauchi Medical Center, Osaka, Japan, 7Amgen Inc., Thousand Oaks, CA, 8Amgen Inc., Thousand Oaks, 9UCB Pharma, Brussels, Belgium, 10Geneva University Hospital, Geneva, Switzerland

    Background/Purpose: Prior studies of anabolic/antiresorptive treatment sequences indicate that using teriparatide first followed by an antiresorptive results in greater bone mineral density (BMD) gains, particularly…
  • Abstract Number: 0115 • ACR Convergence 2020

    Improving Osteoporosis Screening in Men at a Resident-run Primary Care Clinic: A Quality Improvement Project

    Khiem Vu1, Chima Ohadugha1, Kevin Dao1, Rabih Nayfe2 and Andrew Mangano1, 1Grand Strand Medical Center, Myrtle Beach, SC, 2Carolina Health Specialists - Rheumatology, Myrtle Beach, SC

    Background/Purpose: There are known indications for osteoporosis screening in women. However, osteoporosis also occurs in men and fragility fractures are linked to increased morbidity and…
  • Abstract Number: 0188 • ACR Convergence 2020

    The Risk of Fractures in a Community-based Cohort of Patients with Rheumatoid Arthritis Compared with the Background Population

    Lisa Theander1, Jan Åke Nilsson2, Minna Willim3, Lennart T.H. Jacobsson4 and Carl Turesson5, 1Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Sweden, Malmö, Sweden, 2Rheumatology, Department of Clinical Sciences, Malmö, Lund University. Department of Rheumatology, Skåne University Hospital, Malmö and Lund, Sweden, Malmö, Sweden, 3Rheumatology, Department of Clinical Sciences, Lund, Lund University. Department of Rheumatology, Skåne University Hospital, Malmö and Lund, Sweden, Malmö, Sweden, 4Rheumatology, Department of Clinical Sciences, Malmö, Lund University. Department of Rheumatology and inflammation research, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, 5Rheumatology, Department of Clinical Sciences Malmö, Lund University, Department of Rheumatology, Skåne University Hospital, Malmö, Sweden., Malmö, Sweden

    Background/Purpose: Rheumatoid Arthritis (RA) has been associated with increased risk of osteoporosis and fractures. We have recently presented results on DXA measurements over 10 years…
  • Abstract Number: 1974 • ACR Convergence 2020

    Validation of a Deep Learning Based Algorithm to Diagnose Vertebral Compression Fractures

    John Page1, Franklin Moser2, Marcel Maya3, Ravi Prasad3 and Barry Pressman2, 1Amgen, Inc, Thousand Oaks, CA, 2Cedars-Sinai Medical Center, Los Angeles, CA, 3Cedars-Sinai Medical Center, Los Angeles

    Background/Purpose: Vertebral Compression Fractures are common in patients above age 50, but are often undiagnosed.  Patients with one VCF are at higher risk of other…
  • Abstract Number: 1167 • 2019 ACR/ARP Annual Meeting

    To Evaluate Spine Ankylosis, Vertebral Fractures and Bone Fragility on a Single Imaging Exam in Patients with Ankylosing Spondylitis: Myth or Reality?

    caroline Morizot1, Marine Fauny 2, Edem Allado 3, Frank Verhoeven 4, Eliane Albuisson 5, Astrid Pinzano-Watrin 6, Isabelle Chary-Valckenaere 5 and Damien Loeuille 7, 1Department Of rheumatology, Vandoeuvre les Nancy, Lorraine, France, 2CHU Nancy, Vandoeuvre, France, 3CHRU Nancy, VANDOEUVRE, France, 4Univeristy of Franche comté, Besancon, France, 5Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, 6IMoPA. UMR 7365 CNRS, Vandoeuvre, France, 7Rheumatology, Nancy University Hospital and and UMR 7365 CNRS-UL IMoPA, Université de Lorraine, VANDOEUVRE, France

    Background/Purpose: Spine ankylosis is a risk factor of osteoporosis and mortality in ankylosing spondylitis (AS). Recently, thoracic-abdomino-pelvic CT (TAP-CT) has demonstrated its ability to screen…
  • Abstract Number: 2213 • 2019 ACR/ARP Annual Meeting

    Evaluation of Factors Associated with Bone Structure in an SLE Cohort Measured by Clinical 3T MRI and DEXA

    Amit Saxena1, Peter Izmirly 2, Jill Buyon 2, Stephen Honig 2, Xiaoliu Zhang 3, Punam Saha 4, H. Michael Belmont 5 and Gregory Chang 2, 1New York University School of Medicine, New York, NY, 2NYU School of Medicine, New York, 3University of Iowa, Iowa City, 4University of Iowa Healthcare, Iowa City, 5New York University School of Medicine, Ney York

    Background/Purpose: Osteoporosis and bone fractures are a frequent cause of morbidity in systemic lupus erythematosus (SLE), and are felt to be related both to disease…
  • Abstract Number: 2730 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Romosozumab vs Placebo Among Patients with Mild-to-Moderate Chronic Kidney Disease

    Paul Miller1, Arkadi Chines 2, Ben-Hur Albergaria 3, Evelien Gielen 4, Bente Langdahl 5, Akimitsu Miyauchi 6, Mark Vanderkelen 7, Cassandra Milmont 2, Judy Maddox 2 and Jonathan Adachi 8, 1Colorado Center for Bone Research at Panorama Orthopedics and Spine Center, Golden, CO, 2Amgen Inc., Thousand Oaks, CA, 3Federal University of Espirito Santo, Vitória, Brazil, 4Gerontology and Geriatrics, Department of Chronic Diseases, Metabolism and Aging, KU Leuven & Center for Metabolic Bone Diseases, UZ Leuven, Leuven, Belgium, 5Aarhus University Hospital, Aarhus, Denmark, 6Miyauchi Medical Center, Osaka, Japan, 7UCB Pharma, Brussels, Belgium, 8McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada

    Background/Purpose: Osteoporosis and renal insufficiency are coexisting disease states in a substantial proportion of postmenopausal women. Since bisphosphonates are generally contraindicated in patients with estimated…
  • Abstract Number: 1192 • 2019 ACR/ARP Annual Meeting

    Effect of a Clinical Decision Support System on a Quality Indicator of Glucocorticoid-induced Osteoporosis and Trends of Drug Treatment in a Japanese Hospital

    Hiroki Ozawa1, Sho Fukui 1, Genki Kidoguchi 1, Takehiro Nakai 2, Satoshi Kawaai 1, Ayako Koido 1, Yukihiko Ikeda 1, Masei Suda 1, Haruyuki Yanaoka 1, Hisanori Shimizu 1, Hiromichi Tamaki 1, Tokutaro Tsuda 1, Mitsumasa Kishimoto 3, Kenichi Yamaguchi 1 and Masato Okada 1, 1St.Luke International Hospital Immuno-Rheumatology Center, Tokyo, Japan, 2St.Luke International Hospital Immuno-Rheumatology Center, Tokyo, Tokyo, Japan, 3Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan

    Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a common, preventable and treatable complication of glucocorticoid therapy. We defined quality indicator (QI) for GIOP and took a hospital-wide…
  • Abstract Number: 2214 • 2019 ACR/ARP Annual Meeting

    Assessment of Bone Quality by Trabecular Bone Score (TBS) in Systemic Lupus Erythematosus Patients

    Andrea Casabella 1, Sabrina Paolino 2, Alberto Sulli3, Elisa Alessandri 4, Vanessa Smith 5, Barbara Ruaro 6, Carmen Pizzorni 2 and Maurizio Cutolo 7, 11 Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, 2Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, 3Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, 4Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genova, 5Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium; Dept. of Internal Medicine, Ghent University, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium, Gent, Belgium, 61 Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 2 Cardinal Ferrari Centre, S. Stefano Rheabilitation, Fontanellato (Parma), Italy, Genoa, Italy, 7Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy

    Background/Purpose: Systemic lupus erythematosus (SLE) patients show an increased risk of low bone mass as a result of multifactorial events: physical inactivity, persistent inflammation, low…
  • Abstract Number: 1333 • 2019 ACR/ARP Annual Meeting

    The Comparative Risk of Osteoporotic Fractures Among Patients with Rheumatoid Arthritis Receiving TNF Inhibitors versus Other Biologics: A Nation-wide Cohort Study in Korea

    Eun Hye Park1, Anna Shin 2, Yaa-Hui Dong 3, You-Jung Ha 1, Yun Jong Lee 4, Eun Bong Lee 5, Yeong-Wook Song 6 and Eun Ha Kang 1, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, 2Seoul National University Bundang Hospital, Seongnam, Republic of Korea, 3Graduate Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan (Republic of China), 4Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, 5Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul, 6Seoul National University Hospital, Seoul, Republic of Korea

    Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of osteoporosis and osteoporotic fracture, but little is known about comparative risk of osteoporotic fractures between…
  • Abstract Number: 2215 • 2019 ACR/ARP Annual Meeting

    Modeling-Based Bone Formation Persists in the Femoral Neck Despite Remodeling Inhibition in Subjects Treated with Denosumab

    David Dempster1, Peter Butler 2, Mathias Bostrom 3, Jeri Nieves 1, Hua Zhou 4, Li Chen 2, Nicola Pannacciulli 2, Rachel Wagman 2 and Felicia Cosman 1, 1Columbia University, New York, NY, 2Amgen Inc., Thousand Oaks, CA, 3Hospital for Special Surgery, New York, NY, 4Helen Hayes Hospital, West Haverstraw, NY

    Background/Purpose: Denosumab (DMAb) is a potent antiresorptive agent, but findings in non-human primates suggest that modeling-based bone formation (MBBF) may persist despite DMAb treatment (Ominsky…
  • Abstract Number: 1872 • 2019 ACR/ARP Annual Meeting

    Worsening Trends in Osteoporosis Management in the Medicare Population: 2010-2014

    Jeffrey Curtis1, Shanette G. Daigle 2, Setareh A. Williams 3, Richard Weiss 3, Yamei Wang 4 and Tarun Arora 2, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, 3Radius Health, Inc, Waltham, 4Radius Health, Inc, Waltham

    Background/Purpose: Osteoporotic fractures are an important public health burden, and with an increasing aging population, the number of Americans at risk of fractures is projected…
  • Abstract Number: 2216 • 2019 ACR/ARP Annual Meeting

    Bone Mineral Density of the Spine, Hip, and Distal Radius in Patients with Postmenopausal Osteoporosis

    KEN NAKASEKO1, 1Department of Orthopaedic Surgery and Rheumatology Kuwana City Medical Center, kuwana mie, Japan

    Background/Purpose: Bone mineral density (BMD) is used for the diagnosis of osteoporosis, predicting future fracture risk, and monitoring osteoporosis treatment. Osteoporosis is defined as BMD…
  • Abstract Number: 1873 • 2019 ACR/ARP Annual Meeting

    Geisinger HiROC Performance 2017-2018: Continuing to Narrow the Post-Fracture Treatment Gap

    Thomas Olenginski1 and Karen Mackiewicz 2, 1Geisinger Medical Center, Danville, PA, 2Geisinger, Danville, PA

    Background/Purpose: The morbidity and mortality of osteoporotic fractures threaten our aging population. Despite advances in new therapies for osteoporosis and technology to more effectively communicate, fewer…
  • Abstract Number: 2217 • 2019 ACR/ARP Annual Meeting

    DEXA Does Not Accurately Reflect FRAX Score in Patients with Autoimmune Disease on Corticosteroids

    Sima Terebelo1, Madina Abduraimova 1, Latoya Freeman-Beman 1, Naureen Kabani 2, Joshy Pathiparampil 1, Olga Dvorkina 2 and Ellen M Ginzler 3, 1SUNY Downstate Medical Center, Brooklyn, NY, 2SUNY Downstate Medical Center, Brooklyn, 3State University of New York Downstate Medical Center, Brooklyn, NY

    Background/Purpose: Osteoporosis (OP) is a problem in the aging population.  Patients with autoimmune disease are at increased risk for OP given their history of steroid…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology